Stock research
Healthcare · Biotechnology
Basis: Adjusted daily closes.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.
Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies